Newsfeed

Every published oncology item from an approved source, most recent first. No account required — this is the unfiltered stream, not personalized to any follows.

Items are tagged with the biomarkers and tumour types they resolve to; each tag opens that record, and every record’s page carries the same items back.

This demo serves a captured snapshot of the feed, not a live connection to the sources.

PubMed Central · Oct 1, 2026
Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed.
- non-small cell lung cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
A Functionally Constrained Immune Ecosystem in Microsatellite-stable Colorectal Cancer Resolved by Single-cell and Exome Profiling.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Hereditary Diffuse Gastric Cancer With Poorly Differentiated Gallbladder Adenocarcinoma: A Case Report Suggesting Carcinogenesis in the Stomach and Gallbladder Caused by a Pathogenic Germline Variant in CDH1.
- gastric cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Combined Pathological Response and PEPI Score Improves Long-term Prognostic Stratification in HR-positive Breast Cancer Following Neoadjuvant Endocrine Therapy.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Role of EMP2 and Del-1 in Tamoxifen-resistant Breast Cancer Cells.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.
- pancreatic cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Multicohort Construction, Immune Landscape Analysis, and PCOLCE2 Functional Validation of an Inflammation-Related Prognostic Model in Colorectal Cancer.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.
- urothelial carcinoma (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Multi-omics Investigations of Immune Microenvironment of Human Colorectal Cancer.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Factors Affecting Postoperative Delirium in Patients With Colorectal Cancer.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer.
- pancreatic cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Integrated Single-Cell and Spatial Transcriptomics Reveal SERPINE1 as a Key Link Between Macro_SPP1 Macrophages and Stromal Remodeling in Gastric Cancer.
- gastric cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Impact of Non-curative Endoscopic Submucosal Dissection on Minimally Invasive Distal Gastrectomy and on Robotic Versus Laparoscopic Approaches in pT1 Gastric Cancer.
- gastric cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Tumor Suppressive Role of Hsa-miR-328-3p in Colon Cancer by Regulating EN2.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Oct 1, 2026
Anti-gicerin Antibody Suppresses Early Pulmonary Metastatic Colonization of B16F10 Melanoma Cells.
- melanoma (tumour type)
Read at PubMed Central
U.S. Food and Drug Administration · Sep 4, 2026
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View original at U.S. Food and Drug Administration
U.S. Food and Drug Administration · Sep 4, 2026
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults....
- ERBB2 (biomarker)
- breast cancer (tumour type)
View original at U.S. Food and Drug Administration
U.S. Food and Drug Administration · Sep 4, 2026
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.
- breast cancer (tumour type)
View original at U.S. Food and Drug Administration

Newsfeed

Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed.

A Functionally Constrained Immune Ecosystem in Microsatellite-stable Colorectal Cancer Resolved by Single-cell and Exome Profiling.

Hereditary Diffuse Gastric Cancer With Poorly Differentiated Gallbladder Adenocarcinoma: A Case Report Suggesting Carcinogenesis in the Stomach and Gallbladder Caused by a Pathogenic Germline Variant in CDH1.

Combined Pathological Response and PEPI Score Improves Long-term Prognostic Stratification in HR-positive Breast Cancer Following Neoadjuvant Endocrine Therapy.

Role of EMP2 and Del-1 in Tamoxifen-resistant Breast Cancer Cells.

Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer.

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer.

Multicohort Construction, Immune Landscape Analysis, and PCOLCE2 Functional Validation of an Inflammation-Related Prognostic Model in Colorectal Cancer.

Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.

Multi-omics Investigations of Immune Microenvironment of Human Colorectal Cancer.

Factors Affecting Postoperative Delirium in Patients With Colorectal Cancer.

Impact of PI-RADS During Active Surveillance for Prostate Cancer on Pathological Findings at Repeat Biopsy.

Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer.

Integrated Single-Cell and Spatial Transcriptomics Reveal SERPINE1 as a Key Link Between Macro_SPP1 Macrophages and Stromal Remodeling in Gastric Cancer.

Impact of Non-curative Endoscopic Submucosal Dissection on Minimally Invasive Distal Gastrectomy and on Robotic Versus Laparoscopic Approaches in pT1 Gastric Cancer.

Tumor Suppressive Role of Hsa-miR-328-3p in Colon Cancer by Regulating EN2.

Anti-gicerin Antibody Suppresses Early Pulmonary Metastatic Colonization of B16F10 Melanoma Cells.

Oncology (Cancer)/Hematologic Malignancies Approval Notifications

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

FDA Grants Accelerated Approval to a New Breast Cancer Treatment